Gyre Therapeutics (GYRE) Share-based Compensation Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.95% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.93% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.55% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 30.98% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 174.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 174.11% |
| Mar 31, 2026 | 130.84% |
| Dec 31, 2025 | 86.36% |
| Sep 30, 2025 | 72.36% |
| Jun 30, 2025 | 37.83% |
| Mar 31, 2025 | -0.52% |
| Dec 31, 2024 | 43.47% |
| Sep 30, 2024 | -30.73% |
| Jun 30, 2024 | -74.66% |
| Mar 31, 2024 | -77.95% |
| Dec 31, 2023 | -28.67% |
| Sep 30, 2023 | -54.90% |
| Jun 30, 2023 | -52.57% |
| Mar 31, 2023 | -36.10% |
| Dec 31, 2022 | -52.29% |
| Sep 30, 2022 | -34.61% |
| Jun 30, 2022 | -27.37% |
| Mar 31, 2022 | -14.67% |
| Dec 31, 2021 | -2.64% |
| Sep 30, 2021 | 0.52% |